Looks like you clickedhttps://www.astrazeneca-us.com/media/statements/2022/first-participant-dosed-in-supernova-phase-I-III-trial-evaluating-azd5156-a-next-generation-long-acting-antibody-combination-for-prevention-of-covid-19.html
If you do not want to visit that page, you can close this browser tab.
